Financhill
Buy
58

ALNY Quote, Financials, Valuation and Earnings

Last price:
$289.19
Seasonality move :
21.07%
Day range:
$288.74 - $298.23
52-week range:
$146.79 - $304.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.02x
P/B ratio:
330.48x
Volume:
930.2K
Avg. volume:
1M
1-year change:
95.55%
Market cap:
$38.1B
Revenue:
$2.2B
EPS (TTM):
-$2.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALNY
Alnylam Pharmaceuticals
$581.2M -$0.37 -5.16% -5.09% $320.62
AXSM
Axsome Therapeutics
$119.3M -$1.35 61.04% -35.15% $176.53
BBIO
BridgeBio Pharma
$57.7M -$1.00 4530.37% -18.53% $58.78
BMRN
Biomarin Pharmaceutical
$738.7M $0.95 7% 86.93% $95.91
PFE
Pfizer
$14.1B $0.67 1.01% 5555.3% $29.50
VIR
Vir Biotechnology
$8.6M -$0.84 153.31% -27.9% $17.88
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALNY
Alnylam Pharmaceuticals
$292.58 $320.62 $38.1B -- $0.00 0% 16.02x
AXSM
Axsome Therapeutics
$105.76 $176.53 $5.2B -- $0.00 0% 11.82x
BBIO
BridgeBio Pharma
$32.84 $58.78 $6.2B -- $0.00 0% 48.69x
BMRN
Biomarin Pharmaceutical
$58.48 $95.91 $11.2B 21.74x $0.00 0% 3.92x
PFE
Pfizer
$23.04 $29.50 $131B 16.70x $0.43 7.38% 2.10x
VIR
Vir Biotechnology
$4.51 $17.88 $623.5M -- $0.00 0% 43.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALNY
Alnylam Pharmaceuticals
89.88% 1.597 2.91% 2.84x
AXSM
Axsome Therapeutics
77.32% 1.593 3.16% 1.90x
BBIO
BridgeBio Pharma
925.32% 1.067 28.12% 4.31x
BMRN
Biomarin Pharmaceutical
9.32% -0.133 4.39% 3.20x
PFE
Pfizer
40.42% 0.423 42.46% 0.88x
VIR
Vir Biotechnology
-- 2.939 -- 5.84x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
AXSM
Axsome Therapeutics
$111.7M -$55.5M -103.06% -309.19% -46.91% -$43.7M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
BMRN
Biomarin Pharmaceutical
$593.6M $223.9M 8.4% 9.62% 32.34% $157.6M
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B
VIR
Vir Biotechnology
$1.8M -$139.6M -45.02% -45.02% -7779.1% -$79.7M

Alnylam Pharmaceuticals vs. Competitors

  • Which has Higher Returns ALNY or AXSM?

    Axsome Therapeutics has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -48.92%. Alnylam Pharmaceuticals's return on equity of -- beat Axsome Therapeutics's return on equity of -309.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
    AXSM
    Axsome Therapeutics
    91.94% -$1.22 $234.6M
  • What do Analysts Say About ALNY or AXSM?

    Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.53 which suggests that it could grow by 66.92%. Given that Axsome Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
    AXSM
    Axsome Therapeutics
    13 0 0
  • Is ALNY or AXSM More Risky?

    Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

  • Which is a Better Dividend Stock ALNY or AXSM?

    Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALNY or AXSM?

    Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than Axsome Therapeutics quarterly revenues of $121.5M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 11.82x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALNY
    Alnylam Pharmaceuticals
    16.02x -- $594.2M -$57.5M
    AXSM
    Axsome Therapeutics
    11.82x -- $121.5M -$59.4M
  • Which has Higher Returns ALNY or BBIO?

    BridgeBio Pharma has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -143.55%. Alnylam Pharmaceuticals's return on equity of -- beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About ALNY or BBIO?

    Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 78.98%. Given that BridgeBio Pharma has higher upside potential than Alnylam Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
    BBIO
    BridgeBio Pharma
    10 3 0
  • Is ALNY or BBIO More Risky?

    Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

  • Which is a Better Dividend Stock ALNY or BBIO?

    Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALNY or BBIO?

    Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 48.69x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALNY
    Alnylam Pharmaceuticals
    16.02x -- $594.2M -$57.5M
    BBIO
    BridgeBio Pharma
    48.69x -- $116.6M -$167.4M
  • Which has Higher Returns ALNY or BMRN?

    Biomarin Pharmaceutical has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 24.92%. Alnylam Pharmaceuticals's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 9.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
    BMRN
    Biomarin Pharmaceutical
    79.66% $0.95 $6.4B
  • What do Analysts Say About ALNY or BMRN?

    Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 64%. Given that Biomarin Pharmaceutical has higher upside potential than Alnylam Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is ALNY or BMRN More Risky?

    Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

  • Which is a Better Dividend Stock ALNY or BMRN?

    Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALNY or BMRN?

    Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 3.92x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALNY
    Alnylam Pharmaceuticals
    16.02x -- $594.2M -$57.5M
    BMRN
    Biomarin Pharmaceutical
    3.92x 21.74x $745.1M $185.7M
  • Which has Higher Returns ALNY or PFE?

    Pfizer has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 21.63%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About ALNY or PFE?

    Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 28.03%. Given that Pfizer has higher upside potential than Alnylam Pharmaceuticals, analysts believe Pfizer is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
    PFE
    Pfizer
    7 15 1
  • Is ALNY or PFE More Risky?

    Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock ALNY or PFE?

    Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.38% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios ALNY or PFE?

    Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Pfizer's net income of $3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALNY
    Alnylam Pharmaceuticals
    16.02x -- $594.2M -$57.5M
    PFE
    Pfizer
    2.10x 16.70x $13.7B $3B
  • Which has Higher Returns ALNY or VIR?

    Vir Biotechnology has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -6742.75%. Alnylam Pharmaceuticals's return on equity of -- beat Vir Biotechnology's return on equity of -45.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
    VIR
    Vir Biotechnology
    93.94% -$0.88 $1B
  • What do Analysts Say About ALNY or VIR?

    Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Vir Biotechnology has an analysts' consensus of $17.88 which suggests that it could grow by 296.34%. Given that Vir Biotechnology has higher upside potential than Alnylam Pharmaceuticals, analysts believe Vir Biotechnology is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
    VIR
    Vir Biotechnology
    2 2 0
  • Is ALNY or VIR More Risky?

    Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.699%.

  • Which is a Better Dividend Stock ALNY or VIR?

    Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALNY or VIR?

    Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than Vir Biotechnology quarterly revenues of $1.8M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than Vir Biotechnology's net income of -$121M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 43.14x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALNY
    Alnylam Pharmaceuticals
    16.02x -- $594.2M -$57.5M
    VIR
    Vir Biotechnology
    43.14x -- $1.8M -$121M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Forge Global Stock Go Down?
Why Did Forge Global Stock Go Down?

Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…

Is GlobalFoundries On The Verge Of A Breakout?
Is GlobalFoundries On The Verge Of A Breakout?

GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…

Is Dick’s Sporting Goods Buying Foot Locker Smart?
Is Dick’s Sporting Goods Buying Foot Locker Smart?

Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
WIX alert for May 22

Wix.com [WIX] is up 0.98% over the past day.

Buy
81
DY alert for May 22

Dycom Industries [DY] is down 0.5% over the past day.

Sell
50
FICO alert for May 22

Fair Isaac [FICO] is down 0.34% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock